The FDA’s ImportShield Program (FISP) was launched in August 2025 to modernize how the agency reviews imported products. After just four months, an initial review found that the centralized program increased processing speed by 66 percent, boosted monthly volume capacity by 33 percent, and reduced staff hours by 20 percent, saving about 3,388 hours per month. Formerly known as the Nationalized Entry Review Program, FISP consolidates five regional import‑review teams into a single nationwide operation and has already shown its value in screening millions of shipments.
“Whether it’s detecting counterfeit medications or identifying contaminated food products, the FDA ImportShield Program and other modernization efforts add a powerful new layer of protection for American families”.
By combining time‑zone coverage and commodity expertise under unified management, FISP improves efficiency, consistency and accountability in import decision‑making. Nationwide alerts allow investigators to stop high‑risk products such as tainted infant formula or counterfeit drugs at all ports once a threat is detected at any single location. The FDA has also begun upgrading its technology infrastructure; an advanced review platform will integrate multiple tools and databases so investigators can access comprehensive information quickly while maintaining connectivity with Customs and Border Protection systems. With import‑review workload rising from 58 million lines in 2024 to 75 million lines in 2025, these changes aim to strengthen U.S. border oversight and ensure dangerous products are kept out while legitimate goods flow efficiently.
Key Takeaway for Manufacturers
The FDA ImportShield Program centralizes import‑review operations and introduces new technology and real‑time alerts, dramatically improving processing speed and oversight at U.S. ports; manufacturers should expect heightened scrutiny and faster, more consistent decisions on imported products.
Need help navigating evolving FDA requirements?
Dawa Medical works with manufacturers to simplify regulatory processes, support U.S. market entry, and build strong distribution strategies.
Contact Dawa Medical
